The case for MiniMed (MMED) after its fiscal first-quarter print is straightforward: $843 million in revenue, 16% organic growth, and a product pipeline executing ahead of schedule. What complicates it is a 9.9% adjusted EBITDA margin that, taken at face value, looks like a business burning oxygen while it scales.
Strip out two items and the picture shifts. A $12 million foreign exchange remeasurement charge consumed roughly 140 basis points of margin, and an $8 million pull-forward of investment spending tied to the MiniMed Fit FDA submission and the Flex commercial launch took another 90. CFO Chad Spooner said neither item is structural. Excluding both, adjusted EBITDA margin would have been 12.2%. The company reaffirmed its fiscal 2027 EBITDA margin guidance of approximately 16%, and Spooner noted Simplera sensor yields are tracking better than originally modeled, which he expects to lift gross margins in the second half of the year.
The unit-economics read
The more interesting signal is in the product line. U.S. new pumps sold grew over 20% year-over-year, driven by the MiniMed Flex insulin pump, which began shipping in late June. CGM attachment rate reached 69%, up 500 basis points year-over-year. Together, CGM and consumables accounted for 82% of revenue in the quarter, the kind of recurring-revenue concentration that makes a hardware launch durable rather than episodic. New MiniMed prescribers rose 24% year-over-year. Competitor conversions, CEO Que Dallara said, have doubled versus a year ago. More than half of MiniMed Go orders came from patients new to MiniMed.
Type 2 diabetes is central to the growth case. Approximately 40% of new U.S. pump starts are Type 2 patients, a share that continued into Q1. Real-world data on more than 6,500 Type 2 users published earlier this year showed those following MiniMed's recommended SmartGuard settings averaged 82% time in range, 12 points above American Diabetes Association guidelines.
The counterargument
The counterargument runs on two tracks. First, Q1 organic growth included an extra week in MiniMed's fiscal calendar, estimated at 4 to 6 points of the headline 16% figure; strip it out and underlying growth was low double digits. Second, reported free cash flow was negative $90 million for the quarter, with $111 million consumed by separation and standup activities. Excluding those items, MiniMed generated $21 million of positive free cash flow. The company ended Q1 with approximately $207 million in cash, no debt, and an undrawn $500 million revolver. The standalone cost structure is still being assembled: the company has exited 17 of its approximately 160 transition services agreements with Medtronic, with most remaining exits expected in calendar 2027.
On balance, the line to watch is the pipeline schedule. MiniMed Flex received CE Mark approval ahead of its original year-end target, with a European commercial launch planned for November. MiniMed Fit's 510(k) was filed ahead of schedule, with a full U.S. launch expected by summer 2027. Vivera enrollment in its U.S. clinical trial is complete, with a launch expected in the second half of calendar 2027. The full-year organic revenue growth outlook was raised to approximately 10.5% from approximately 10%.